Related Experiment Video

Updated: Aug 24, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling

Rongrong Ge1, Vaishali Rajeev, Gayathri Subramanian

  • 1Division of Medical Oncology, Department of Internal Medicine, UMDNJ-Robert Wood Johnson Medical School and The Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Biochemical Pharmacology
|June 9, 2004
PubMed

Insights

Novel quinazoline-derived inhibitors (TbetaKIs) block transforming growth factor-beta (TGFbeta) signaling by inhibiting type I receptor kinase activity. These compounds show potential for treating cancer and fibrosis by disrupting key cellular processes.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Drug Discovery

Background:

  • Transforming growth factor-beta (TGFbeta) is crucial in physiological processes and diseases like cancer and fibrosis.
  • Constitutive activation of TGFbeta signaling pathways drives various pathological conditions.
  • Targeting TGFbeta signaling offers a novel therapeutic strategy for related disorders.

Purpose of the Study:

  • To describe the biological properties of novel quinazoline-derived inhibitors of TGFbeta type I receptor kinase (TbetaKIs).
  • To evaluate the efficacy of TbetaKIs in blocking TGFbeta signaling pathways in vitro.
  • To assess the potential of TbetaKIs as therapeutic agents for cancer and fibrosis.

Main Methods:

  • Synthesis and characterization of quinazoline-derived compounds.
  • In vitro assessment of TbetaKIs' ability to inhibit TGFbeta-induced Smad2 phosphorylation.
  • Evaluation of TbetaKIs' effect on TGFbeta-induced reporter gene activation.
  • Testing TbetaKIs' impact on TGFbeta-mediated growth inhibition and epithelial-mesenchymal transdifferentiation (EMT).

Main Results:

  • TbetaKIs effectively inhibited TGFbeta-induced Smad2 phosphorylation with IC(50) values between 20 and 300 nM.
  • Compounds broadly blocked TGFbeta-induced reporter gene activation.
  • TbetaKIs inhibited TGFbeta-mediated growth inhibition in NMuMG and Mv1Lu cells.
  • TbetaKIs suppressed TGFbeta-induced EMT in NMuMG cells.

Conclusions:

  • Novel chemical TbetaKIs demonstrate potent inhibition of TGFbeta signaling.
  • These TbetaKIs hold promise for development as anti-cancer and anti-fibrosis agents.
  • TbetaKIs serve as valuable tools for studying TGFbeta signal transduction mechanisms.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...